4.1 Therapeutic indications
Mitomycin is used in palliative tumour therapy.
Mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of:
• advanced metastatic gastric carcinoma
• advanced and/or metastatic breast cancer
Furthermore mitomycin is administered intravenously in combined chemotherapy in the case of:
• non-small cell bronchial carcinoma
• advanced pancreatic carcinoma
Intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).